Romiplostim

Romiplostim
Clinical data
Trade names	Nplate, Romiplate
Other names	AMG531
AHFS/Drugs.com	Monograph
MedlinePlus	a609008
License data	EU EMA: by INN; US DailyMed: Romiplostim; US FDA: Nplate;
Pregnancy; category	AU: B3;
Routes of; administration	Subcutaneous
ATC code	B02BX04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Elimination half-life	1 to 34 days
Identifiers
	IUPAC name L-methionyl[human immunoglobulin heavy constant gamma 1-(227 C-terminal residues)-peptide (Fc fragment)] fusion protein with 41 amino acids peptide, (7-7′:10,10′)-bisdisulfide dimer;
CAS Number	267639-76-9 ;
IUPHAR/BPS	6974;
DrugBank	DB05332 ;
ChemSpider	none;
UNII	GN5XU2DXKV;
KEGG	D08990;
ChEMBL	ChEMBL1201832 ;
Chemical and physical data
Formula	C2634H4086N722O790S18
Molar mass	59085.01 g·mol−1
	(what is this?) (verify)

Romiplostim, sold under the brand name Nplate among others, is a fusion protein analog of thrombopoietin, a hormone that regulates platelet production.

The drug was developed by Amgen through a restricted usage program called NEXUS. During development and clinical trials the drug was called AMG531.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.